LOS ANGELES, Nov. 11 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the appointment of Craig A. Dionne, Ph.D. as executive vice president of research and therapeutics. Dr. Dionne recently served as vice president, biological research at Cephalon, Inc., where he directed drug discovery programs in both oncology and neurobiology. During his tenure at Cephalon, Dr. Dionne led many collaborative initiatives with academic research scientists and biopharmaceutical companies, and brought four novel drugs into clinical development.
In his new position at the Prostate Cancer Foundation, Dr. Dionne will be responsible for the scientific vision of the organization and coordination of research initiatives with leading academic and medical centers.
Leslie D. Michelson, vice chairman and CEO of the Prostate Cancer Foundation commented, “Craig brings extensive expertise in drug discovery and development to the PCF. His efforts will be critical to the organization as we seek to accelerate the development of new treatments and a cure for recurrent prostate cancer. We are proud to welcome Craig to our team.”
To learn more about the executive management team of the PCF please visit http://www.prostatecancerfoundation.org/.
About Dr. Dionne
Dr. Dionne has over 16 years experience in the pharmaceutical industry with increasing levels of responsibility throughout his career. He recently co-founded GenSpera, Inc., a privately held biotechnology company focused on the clinical development and partnering of novel prostate cancer therapeutics. Dr. Dionne is a visiting scientist in oncology at the Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine and has previously served as an associate adjunct professor at New York University. He is a named inventor on six patents, three of which relate directly to prostate cancer, and has co-authored more than 50 original research articles.
Dr. Dionne received his B.S. degree in Biochemistry from Louisiana State University and his Ph.D. degree in Biochemistry from the University of Texas. He conducted his post-doctoral fellowship at Dana-Farber Cancer Institute in a joint appointment with Harvard Medical School.
About the Prostate Cancer Foundation
The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research. Founded in 1993, the PCF has raised more than $210 million and provided funding for prostate cancer research to more than 1,100 researchers at 100 institutions worldwide. The PCF has a simple, yet urgent goal: to find better treatments and a cure for recurrent prostate cancer. For more information, visit http://www.prostatecancerfoundation.org/.
Prostate Cancer Foundation
CONTACT: Erika Beck, Director of Communications of the Prostate CancerFoundation, +1-310-570-4705; or Justin Jackson of Burns McClellan,+1-212-213-0006, for the Prostate Cancer Foundation
Web site: http://www.prostatecancerfoundation.org/
